Biomerica, Inc.
BMRA Healthcare Medical Devices
Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025. In the quarter to May 2026, revenue grew 17.0%, EPS grew 37.8% and free cash flow fell 35.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow BMRA
Biomerica, Inc. (BMRA) Altman Z-score
Biomerica, Inc.'s Altman Z-score for fiscal 2026 is −12.45, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −12.45 | (0.89) |
| FY2025 | −11.56 | (5.50) |
| FY2024 | −6.06 | (5.86) |
| FY2023 | −0.21 | (5.74) |
| FY2022 | 5.54 | (0.24) |
| FY2021 | 5.78 | (6.09) |
| FY2020 | 11.87 | 7.05 |
| FY2019 | 4.82 | (14.86) |
| FY2018 | 19.68 | (0.96) |
| FY2017 | 20.64 | 8.47 |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.23 | — | 0.27 | |
| Retained earnings / total assets | (8.42) | — | −11.79 | |
| EBIT / total assets | (0.79) | — | −2.60 | |
| Market value of equity / total liabilities | 1.69 | — | 1.01 | |
| Sales / total assets | 0.66 | — | 0.66 | |
| Altman Z-score | Distress zone | −12.45 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −30.60 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| WOK WORK Medical Technology Group LTD compare | 1,088× |
| NMTC NeuroOne Medical Technologies Corporation compare | −3.7× |
| CTSO Cytosorbents Corporation compare | −9.2× |
| AEMD Aethlon Medical, Inc. compare | −10.8× |
| BMRA Biomerica, Inc. | −12.4× |
| TNON Tenon Medical, Inc. compare | −13.0× |
| BTCY Biotricity Inc. compare | −33.3× |
| PETV PetVivo Holdings, Inc. compare | −38.6× |
| AMIX Autonomix Medical, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets